Company insight
A game-changing digital platform
The pharmaceutical industry has historically been risk-averse and slow to adopt technology. PCI Pharma Services is blazing a trail in digitalisation.
ccording to Wayne Hull, global chief digital and technology officer at PCI, “PCI Pharma Services is recognised in the industry as a leader when it comes to providing world-class customer service. In order to retain that leadership position going forward, digital experiences and capabilities are essential.” The company is now two years into a three-year corporate digital transformation strategy that is already differentiating the company, and providing real and measurable returns – the pci | bridge platform is a prime example of this.
A
pci | bridge makes its customer’s lives easier by giving them real-time visibility into their clinical and commercial supply
Address clinical trial management needs
Clinical trial services is the fastest- growing and most logistics-heavy division at PCI. Clinical trial activity intensified further during the coronavirus pandemic, with a greater demand for new Covid-19 tests and therapies. While pci | bridge was not developed specifically in response to Covid-19, PCI had to scale up to meet the moment.
“Covid-19 highlighted a need we were already focused on,” says Tim Roberts, vice-president for global sales for clinical services, PCI. “The level of detail in the platform is a big differentiator. Users can easily navigate among clinical trials and drill down into deep layers of data to maximise transparency.”
“We are always looking to the future and can see the potential that digitalisation holds for the pharma and biopharma supply chain. pci | bridge is a leading-edge client experience that will continue to evolve as the business requires.”
Wayne Hull
chain to enable closer collaboration with PCI’s teams, as well as provide instantaneous data and insights to inform decision-making. “We wanted to build a very customer-centric user experience (UX) platform with information that is relevant to customers’ projects and their relationship with PCI,” says Morgan Brandt, director, digital products at PCI. “We also want to provide as much transparency as possible, saving time and resources to ultimately help bring life-changing therapies to patients faster.”
16
The pci | bridge platform helps customers in their day-to-day operations to better manage the clinical trials process from start to finish, from inventory to shipments, with seamless functionality. A key feature of pci | bridge is its ability to pull in real- time data across inventory, production and distribution.
Built from the outside in PCI wanted to go beyond data to create a consistent yet technologically leading platform built around the entire customer experience. PCI worked with customers
to illuminate their desires for a better way to work together, such as more supply chain visibility and less time spent on manual activity to manage the PCI relationship.
“The benefits of using pci | bridge is that it eliminates the need for clients to constantly reach out to the project teams for updates,” says Kevin Gregorczyk, director, development operations at eFFECTOR Therapeutics, which participated in the development process. “Now, we will have that information at our fingertips and can instead focus on the bigger picture with PCI, such as what’s coming next.”
The digital journey continues While clinical trials are often the entry point for PCI customers, pci | bridge can be used throughout the product life cycle. The company is, therefore, continuing to invest and enhance the platform with more integrations and other expanded functionality. For example, PCI plans to integrate pci | bridge into systems customers already use, such as interactive response technology (IRT) systems, which is an essential component of clinical trial management. “We are always looking to the future and can see the potential that digitalisation holds for the pharma and biopharma supply chain,” says Hull. “pci | bridge is a leading-edge client experience that will continue to evolve as the business requires. Ultimately, if you work in ten systems, we want to eliminate nine so you only have to use one resource for a seamless experience – ultimately making life easier.” ●
https://pci.com Clinical Trials Insight /
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45
